BioCardia reports Q3 2025 results, $6M financing, and regulatory milestones for cell therapies

BioCardia, Inc.

Closed $6.0 million financing with net proceeds of $5.2 million in September 2025.
Net loss decreased to $1.5 million for Q3 2025 from $1.7 million in Q3 2024.
Positive preliminary clinical consultation with Japan’s PMDA for CardiAMP heart failure trial.
Plans to submit Helix transendocardial delivery catheter for FDA DeNovo 510(k) in Q4 2025.
Cash balance of $5.3 million on Sept 30, 2025, providing runway into Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.